Introduction
Accurate non-invasive anatomic evaluation of coronary arteries has become possible with coronary computed tomography angiography (CTA). The strength of coronary CTA is its ability to exclude significant anatomic coronary artery disease (CAD), and provide detailed assessment of atherosclerotic burden and plaque morphology, providing an opportunity for definite diagnosis of CAD and early application of preventive therapies. In symptomatic patients with a low-to-intermediate risk of CAD, coronary CTA is increasingly utilized and is considered an appropriate first-line test. 1 Studies have demonstrated that an upfront coronary CTA strategy can increase the diagnostic yield of invasive catheterizations finding obstructive disease as compared to usual care. 2, 3 The increased diagnostic certainty and opportunity for more targeted treatment when adding coronary CTA have been associated with improved outcomes, including a significant reduction in myocardial infarctions. 3, 4 Nonetheless, the consistent observation of increased rates of ICA and revascularization following coronary CTA suggests that functional testing remains an integral component in the evaluation of CAD. 4 The need to further enhance clinical decision making in the presence of CT documented CAD has driven the development of functional cardiac CT. For both CT myocardial perfusion imaging (CTP) and CT fractional flow reserve (CT FFR) techniques, data from singleand multi-centre studies have rapidly accumulated. In addition, recent reviews and meta-analyses have provided further information on methodologies and diagnostic accuracy for the detection of haemodynamically significant CAD. [5] [6] [7] [8] [9] Considering the fast transition of both CT FFR and CTP from research application to clinical use, the question that now emerges is how to optimally implement these techniques in mainstream practice? Therefore, the aim of this paper is to provide a guide to the clinical application of CT FFR and CTP with an emphasis on their use tailored to the individual patient.
Physical principles FFR derived from coronary CTA
FFR is defined as the ratio of maximal hyperemic flow in the presence of a stenosis in an epicardial artery to the maximum hyperemic flow in the hypothetical case in which the artery is normal. The application of computational fluid dynamics (CFD) to coronary luminal models derived from CT has enabled prediction of coronary blood flow and pressure, and hence the derivation of CT FFR non-invasively. Currently two broad approaches have been described. The first approach is FFR CT (HeartFlow, Inc.) which to date is the only commercially available product and has the largest body of clinical data based on multi-centre trials. Analysis is performed in a remote location, as the technique requires the use of detailed manual coronary luminal contouring and can only be computed using a parallel supercomputer. More recently point-of-care techniques are being introduced, although these are still in the research and development phase.
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Based on CT data, the luminal model of the aortic root and entire coronary tree can be extracted in a semi-automated manner with manual adjustments made as required. Luminal contour precision is paramount to diagnostic accuracy as it is used to reconstruct the finite mesh model upon which the boundary conditions and the fluid analysis are applied. For this reason, the time required to complete each case depends on coronary plaque burden; the higher the disease burden, the longer the likely required processing time. Image quality is also extremely important emphasizing the need for adequate heart rate control and coronary vasodilation during image acquisition. The limited isotropic spatial resolution of most current cardiac CT scanners (0.5 mm) negatively impacts luminal boundary definition.
Boundary conditions refer to the physiological principles or assumptions made at the coronary inlet and outlet regarding flow, resistance and pressure, required for computational fluid analysis. In FFR CT and cFFR (Siemens Healthcare), allometric scaling laws, which assume the flow in the epicardial vessel to be proportional to the left ventricular myocardial mass being perfused, serve as the foundation in which these conditions are determined. In order to account for the effects of hyperemia, microvascular resistance is assumed to decrease predictably at maximal hyperemia throughout the entire myocardium. 13 In CT-FFR (Toshiba Medical Systems), a different set of analysis conditions are used, based on four different cardiac phases with the aim of being more patient specific. The final step is the use of a numerical solution to simulate luminal blood flow. For this purpose, a finite mesh model consisting of millions of tetrahedral 'mesh' elements is derived and at which level governing equations of blood flow are solved using Navier-Stokes equations. These equations are established methods used in the computation of fluid dynamics to describe the motion of viscous fluids in diverse situations including blood flow in vascular systems. Blood is modelled as Newtonian fluid with a constant viscosity in FFR CT and cFFR, but as non-Newtonian fluid in CT-FFR. In the FFR CT model, a 3D representation of mesh elements at all points in the coronary tree, including the bifurcations is generated, whereas reduced order 1D modelling is used in cFFR and CT-FFR. The latter approach may be limited in segments with small vessel diameter near bifurcations, but has the advantage of shorter processing times using a standard desktop workstation at the point of care. More details concerning these individual techniques can be found elsewhere. 7, [10] [11] [12] Myocardial CTP An extensive review on myocardial CTP has recently been published. 8 In brief, CTP is based on the principle that there is a direct relationship between the amount of iodinated contrast material in the myocardium and myocardial blood flow (MBF). Regional differences in myocardial attenuation can occur at any given moment in time due to coronary stenosis, longer contrast arrival pathways in cases of previous bypass surgery or collaterals, microvascular disease or differences in capillary density as in between normal myocardium and densely scarred tissue. The resulting areas of hypoattenuation reflect perfusion defects.
The most common CTP approach is static imaging during which a single CT dataset is obtained during the estimated upslope or peak contrast enhancement during rest and stress. Interpretation relies on a visual assessment alone, or in combination with semi-quantitative measures.
14 Although the use of wide-coverage scanners offer the advantage of temporal uniformity and less artefacts, as well as lower radiation dose and shorter acquisition times, the feasibility of static CTP imaging using lower-end CT scanners that acquire data from sequential heartbeats to cover the heart has been shown as well. The use of dual-energy CT or spectral CT may provide an alternative approach. 9 Another, currently more technically challenging, approach is dynamic CTP during which tissue attenuation curves (TACs) from both the myocardium and arterial blood pool are simultaneously recorded. Several analysis methods have been described, from relatively simple upslope analyses to more complex mathematical modelling based on deconvolution principles. 15 During upslope analyses, only the first part of the TAC is used, and the first-pass transit of the contrast agent is constructed using a linear curve fitting model. The slope and peak enhancement of the region of interest can then be compared to the remote myocardium and arterial blood pool, allowing semi-quantitative evaluation. In contrast, model-based deconvolution approaches provide full quantitative perfusion parameters. Despite its lack of standardization, dynamic CTP may offer significant advantages over static perfusion technique. Practically, serial imaging enhances the ability to differentiate true perfusion defects from artefacts. Moreover, its quantitative nature allows derivation of absolute MBF (defined as mL/100 mL/min) and coronary flow reserve (CFR). 16 CFR, which is calculated as the ratio of hyperemic to rest absolute MBF, is a measure that integrates the haemodynamic effects of focal, diffuse, and microvascular CAD on myocardial tissue perfusion and has emerged as a potential unifying mechanism for angina . and common analysis parameters is provided in Supplementary data online, Table S1 .
Available clinical experience Diagnostic accuracy CT FFR and CTP
Available studies on the diagnostic performance of CT FFR and CTP techniques are summarized in Table 1 , with full details provided in Supplementary data online, Tables S2 and S3, respectively. In addition to data from multicentre trials, 18, 19 several meta-analyses have been published, reporting comparable diagnostic accuracies for CT FFR and CTP as compared to invasive FFR. 6, 8, 9, 20, 21, 22 In general, improved specificity and positive predictive value for lesion specific ischaemia are reported, while the sensitivity and negative predictive value of coronary CTA are preserved. A clinical case example illustrating both CT FFR and CTP in a patient with significant stenosis on coronary CTA is provided in Figure 1 .
Comparative studies
To date, two studies have compared the diagnostic performance of point-of-care CT FFR with CTP using invasive FFR as reference standard. From a prospective CTP registry, additional CT FFR was derived in 72 patients with suspected CAD and invasive FFR correlation available. 23 The authors demonstrated equally high diagnostic accuracy for both techniques (AUC 0.92 for CT FFR and 0.91 for CTP). Equivalent diagnostic performance was also reported by Coenen et al. 24 Notably there was incremental benefit upon integrating CTP 
Outcome data
To date, information on the prognostic implications of CT FFR and CTP remain limited. The PLATFORM trial reported in patients with stable chest pain and planned ICA that at 1-year follow-up, care guided by coronary CTA and selective use of FFR CT was associated with equivalent outcomes and quality of lower and lower costs compared to direct referral to ICA. 26, 27 Clinical registry data showing no adverse cardiac events 1 year after deferral of ICA based on FFR CT >0.80 support the favourable short outcome. 28 Two-year follow-up in the CORE320 trial demonstrated that combined coronary CTA and CTP provides prediction of adverse events that is similar to combined ICA and SPECT perfusion imaging. 29 A sub-study of a trial in patients with recent acute-onset chest pain showed that static CTP could accurately predict mid-term (median 19 months) clinical outcome. 30 Similarly, initial outcome results from a registry on dynamic CTP were published showing that global quantitation of MBF was highly predictive of events, with incremental value over clinical risk factors and coronary CTA. 31 More recently, selective use of CTP in patients with obstructive CAD identified on coronary CTA was shown to allow a five-fold reduction in likelihood of proceeding to ICA.
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Practical guidance for the use of functional CT in patients referred for coronary CTA Figure 2 summarizes the main differences between CT FFR and CTP. Importantly the decision to use CT FFR or CTP requires more than merely comparing reported diagnostic accuracies and will be largely influenced by the patient's clinical presentation, CT image quality, local institutional logistics, and financial reimbursement. A first theoretical guide for CT functional testing in patients referred for coronary CTA, as proposed in Figure 3 , may be useful until additional evidence becomes available.
Considerations before and during acquisition Scan optimization
The accuracy of both CTP and CT FFR is heavily dependent on image quality. CT FFR relies on precise delineation of the coronary lumen and therefore requires optimal image quality. Accordingly, stringent CT image quality control through adherence to established guidelines can improve acceptance rates and accuracy. 18, 28 Notably despite these efforts, studies have reported up to 10-15% rejected examinations because of low image quality. 18, 27 In a highly experienced site, restricted referral to FFR CT in a small proportion (15%) of patients clinically referred for coronary CTA demonstrated a high success rate of 98%. 28 Similarly, vasodilator stress during CTP is associated with up to 15-20 beats per minute increase in heart rate, and thus the administration of beta-blockers prior to stress imaging may help to optimize image quality. 33 Although all types of vasodilator stress agents have been used, most of the published data have been obtained with adenosine. The most practical agent may be regadenoson since it does not require continuous infusion and can be delivered as a single bolus.
Clinical presentation
Studies thus far have only evaluated the diagnostic performance of CT FFR in suspected CAD. In patients with known CAD and a history of myocardial infarction or revascularization [stent placement/ coronary artery bypass grafting (CABG)] the diagnostic performance of CT FFR remains unknown. On the contrary, a large number of CTP studies have included patients with known CAD, and for this reason, CTP may be considered the technique of choice. In patients with coronary stents, improved diagnosis of CAD and in-stent restenosis has been observed when using a combined CTA and CTP imaging strategy as compared to CTA alone. 34 The diagnostic performance of CT functional assessment of patients with prior CABG has not been studied, although a limited number have been included in CTP diagnostic accuracy studies. Theoretically, the delayed contrast arrival seen in the presence of coronary bypass grafts may negatively impact the diagnostic accuracy of CTP. The influence of coronary anomalies or intramyocardial bridging on CT FFR remains unknown. Finally, the need for additional contrast during CTP limits its use in patients with renal dysfunction.
Logistics and costs
Currently, only one CT FFR algorithm has been approved for clinical use and requires the submission of clinical data sets to a commercial company owned core-laboratory located in the USA. While studies thus far suggest that the combination of coronary CTA with CT FFR may reduce overall costs, 26 the cost reduction is predominantly found in patients referred for ICA, yet not demonstrated in patients referred for non-invasive testing. No dedicated cost-analyses are available for CTP. Notably, funding processes in both private and government sectors are often complex. As such, fiscal considerations may prohibit widespread uptake in the short term.
Remote analysis also requires substantial data-transfer capabilities, while considerations pertaining to patient confidentiality and cybersecurity will need to be resolved. Clinical acceptance may be improved by an on-site approach which provides both convenience and favourable costs. On-site analysis however requires manual input for accurate lumen segmentation thus demanding a high standard of local quality control. Adequate training of staff at individual sites is crucial, and future software refinements to further automate the process is desirable.
CTP performed immediately after coronary CTA is an attractive option in cases where prompt diagnosis is needed. The feasibility of adding CTP to coronary CTA in patients with recent acute-onset chest pain has recently been demonstrated 35 staff supervision and is associated with additional costs. Stress CTP images may be particularly prone to motion artefacts. Diagnostic image quality may be improved by reconstruction of multiple cardiac phases to identify the phase with the least cardiac motion. This requires optimal data storage systems, as the data space taken up by CTP files will far exceed that required for rest CTA phases alone. A significant learning curve exists for the interpretation of CTP studies. Accordingly, as with most clinical testing, results may be challenging during the initial rollout phase of test clinical implementation, or in sites that only perform CTP occasionally. Further simplification of workflow and analysis remains needed. In summary, choice for stress agent, additional support, and need for additional scanner time determine costs of CTP with wide geographic variation. For CT FFR, the need for off-site image processing and interpretation vs. costs of software and resource utilization for on-site approaches are the main cost determinants. Whether these added costs can be offset by savings in downstream resource utilization such as prevented invasive catheterizations or invasive functional evaluation may depend on local healthcare models and requires additional evidence.
Considerations during image interpretation
In patients with low-to-intermediate pre-test likelihood of CAD, the negative predictive value of coronary CTA is high, and the majority may only have minor disease (<30% luminal narrowing) or normal scans. In these patients, functional evaluation may not be required. On the other hand, in referred patients that have a higher pre-test likelihood or known CAD, as well as lesions >30% stenosis on the CT angiogram, additional functional testing may be considered. In the majority of patients, CT FFR derived from coronary CTA will most likely allow a definite evaluation of haemodynamically relevant disease. In a subset of 
cases however, including those with non-diagnostic image quality, small vessel lesions, extensive calcified disease, or borderline CT FFR results, functional assessment by means of CTP may be beneficial.
Image quality and extensive disease
Extensively calcified atherosclerosis can reduce the diagnostic certainty of CT FFR. The recent sub-analysis of the NXT trial in patients with an average calcium score of 302 ± 468 reported no statistically significant difference in diagnostic accuracy across calcium score quartiles, although a numerical reduction in diagnostic accuracy of patients with high calcium scores when compared with those with low to mid calcium scores was observed and cases with excessive calcium blooming were excluded. 18, 36 Favourable results with regards to extensive calcifications have recently been reported by Ko et al. 11 who successfully applied a novel on-site CT FFR algorithm in a population with a substantially higher coronary calcium burden (mean: 910.3 ± 1075.6). However, patients with extensive calcification such as with Agatston scores >1000 remain scarce in the literature to date. 18, 28, 36 In a recent direct comparison of CT FFR and CTP, specificity and positive predictive value of CTP was higher compared to CT FFR in patients with calcium scores >173. 23 CTP may therefore be a particularly attractive adjunct in those patients in whom accurate evaluation of coronary anatomy is difficult. Indeed, superior diagnostic accuracy of combined coronary CTA and CTP imaging has been shown in high risk/known CAD patients with elevated calcium scores as compared to coronary CTA or CTP alone. 37, 38 In the presence of coronary anomalies, myocardial bridging, coronary aneurysms CTP may also be the preferred technique at present as in these scenarios CT FFR has not yet been fully established.
In studies so far, CTP can be applied in the majority of cases although motion, cone beam, and beam hardening artefacts are not uncommon and can mimic perfusion defects. Specialized algorithms to reduce such artefacts combined with dedicated, stepwise CTP interpretation can alleviate the impact of artefacts.
14 Careful interpretation by experienced observers has been shown to provide conclusive diagnosis in >95% of cases. 35, 39 Identifiable stenosis Similar to its invasive counterpart, CT FFR is a lesion specific measure that has been developed to assess whether a focal coronary stenosis is likely to benefit from revascularization in addition to medical therapy. Therefore, diseased vessels harbouring intermediate lesions of uncertain flow limiting characteristics represent the primary targets for CT FFR. One of the most experienced sites in clinical use of FFR and myocardial perfusion by CT FFR CT therefore recommends patients with one or two intermediate stenoses (30-70%) in segments > _2 mm on coronary CTA as the main candidates for additional testing with CT FFR. 28 The range of 30-50% diameter stenosis is generally used as the lower threshold for non-invasive functional testing. A lack of consensus regarding the precise cut-off value exists given the imprecise relation between percentage diameter stenosis and ischaemia. While the likelihood of ischaemia is substantially higher in lesions exceeding 50% luminal narrowing, lesions of 30-50% could be considered of potential haemodynamic significance. 40 Patient presentation in combination with disease extent, lesion location, and characteristics as well as local practice generally determine further testing strategy in patients with <50% diameter stenosis.
Borderline CT FFR results
Despite good direct correlations of per vessel CT FFR with invasive FFR, slight underestimations have been reported, indicating that most misclassifications when using a dichotomous interpretation approach will occur around the cut-off point of 0. 24 Future directions: towards a comprehensive and individualized assessment of CAD with CT
The future outlook for functional CT techniques is promising given their potential to more precisely define mechanisms of angina pectoris. A greater understanding of CAD pathophysiology is emerging which in turn requires novel strategies to phenotype ischaemic heart disease for individualized decision-making. CT-based technology may be best positioned to respond to such needs because of its versatility, widespread availability, and ease of use. Patients may present with diverse combinations of pathophysiologic phenotypes. In each of the vessels, any combination of focal vs. diffuse obstructive and nonobstructive atherosclerotic plaques of diverse composition can occur, with varying consequences on coronary pressure and flow. Add to such scenarios the possibility of co-existing microvascular disease and remodelling from hypertrophy, diabetes, hypertension, and the full spectrum of ischaemic heart disease emerges to remind us of the limitations inherent to the techniques we currently use to manage patients across the continuum from early to advanced disease. Although FFR and myocardial ischaemia measurements are generally correlated, this correlation is known not to be one to one, especially among higher risk patients with co-morbidities. Similarly, disagreements between CT FFR and CTP findings may not immediately imply failure of either tool but could provide further clues to the relative contribution of focal epicardial stenosis, diffuse atherosclerosis, and microvascular disease. CT FFR is highly suitable for the evaluation of epicardial lesions of intermediate stenosis. On the other hand, high-resolution perfusion imaging such as CTP may allow non-invasive identification of the more generalized, subendocardial myocardial ischaemia associated with diffuse atherosclerosis with or without microvascular disease. 17, 42 Although still highly speculative at this moment, quantitative CTP may offer in the future a more adequate explanation for persistent angina symptoms in the absence of stenotic coronary arteries and improve risk stratification in these patients. 31, 43 Accordingly, combined with visualization and quantitation of luminal narrowing and coronary plaque, functional CT may become a powerful tool to provide precise and reproducible phenotyping within a relatively short period of time, and may enhance guidance of treatment and monitoring strategies. 44 
Conclusions
In patients with interpretable stenotic coronary arteries and suitable coronary diameter, CT FFR will be the first option for functional assessment. Direct measurement of myocardial perfusion with CTP becomes preferential in the patient with a history of CAD (particularly stent placement), poor image quality CT angiogram, or high coronary calcium burden. In the future, assessment of CFR with CT could provide answers and monitoring options for patients with anginal symptoms in the absence of obstructive CAD. Indeed, as techniques continue to mature, the combination of coronary CTA with CT FFR and/or CTP may become a powerful and accessible diagnostic tool for the comprehensive characterization of atherosclerotic disease, providing a potentially more precise and personalized approach to patients with suspected CAD.
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